Journal
TRENDS IN MOLECULAR MEDICINE
Volume 17, Issue 6, Pages 301-312Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2011.01.011
Keywords
-
Funding
- NINDS NIH HHS [R01 NS052507] Funding Source: Medline
Ask authors/readers for more resources
Despite advances in treatment for glioblastoma multiforme (GBM), patient prognosis remains poor. Although there is growing evidence that molecular targeting could translate into better survival for GBM, current clinical data show limited impact on survival. Recent progress in GBM genomics implicate several activated pathways and numerous mutated genes. This molecular diversity can partially explain therapeutic resistance and several approaches have been postulated to target molecular changes. Furthermore, most drugs are unable to reach effective concentrations within the tumor owing to elevated intratumoral pressure, restrictive vasculature and other limiting factors. Here, we describe the preclinical and clinical developments in treatment strategies of GBM. We review the current clinical trials for GBM and discuss the challenges and future directions of targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available